Approval for Covidien's Nellcor - Analyst Blog

By
A A A

Leading health care products company, Covidien plc. ( COV ) recently won the U.S. Food and Drug Administration (FDA) 510(k) approval as well as the European Economic Area (EEA) CE Mark clearance for its Nellcor Bedside Respiratory Patient Monitoring system. The device is used for quick detection and monitoring of severe respiratory complications.

The addition of the Nellcor Bedside Respiratory Patient Monitoring system from Covidien's oximetry and monitoring products portfolio under the Medical Devices business division is poised to attract healthy revenue opportunities for the company. The system meets the required standards and will be available in the U.S. and EEA in the coming few months.

The Nellcor Bedside Respiratory Patient Monitoring system continuously monitors blood oxygenation as well as pulse rate and allows physicians easy access to patients' respiratory history, thereby enabling faster treatment and improved standards of care.

The system has a multicolor screen that allows effortless observations. It can also be connected to the Nellcor OxiNet III Remote Respiratory Monitoring system, allowing physicians to monitor multiple patients from a central station.

Earlier in June, the company launched the Nellcor SpO2 single parameter module in North America, European Economic Area (EEA) and other select overseas markets. In July, Covidien received the FDA approval for the Nellcor Bedside SpO2 Patient Monitoring System. It is now available for sale in the U.S. This underlines Covidien's commitment to new products and technology roll out, focusing on high-growth markets.

With market capitalization of $28.52 billion, Covidien is a leading developer, manufacturer and distributor of medical devices and services on a global scale. Its business segments overlap with the business of its competitors such as Becton, Dickinson and Company ( BDX ) and CR Bard Inc. ( BCR ) among others.

We currently have a Neutral recommendation on Covidien, which carries a short-term Zacks #3 Rank (Hold rating).


 
BARD C R INC (BCR): Free Stock Analysis Report
 
BECTON DICKINSO (BDX): Free Stock Analysis Report
 
COVIDIEN PLC (COV): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: BCR , BDX , COV , EEA

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Cheap Ways to Sleep Better
Cheap Ways to Sleep Better          

Stocks

Referenced

Most Active by Volume

105,679,298
  • $16.13 ▼ 0.19%
43,130,824
  • $101.32 ▲ 0.74%
24,108,376
  • $59.80 ▲ 7.34%
22,524,427
  • $26.15 ▼ 1.06%
22,194,114
  • $24.65 ▼ 0.96%
21,835,360
  • $99.05 ▲ 0.15%
20,872,575
  • $34.94 ▼ 0.60%
20,561,803
    $74.57 unch
As of 8/22/2014, 04:02 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com